Effect of β-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction

Pérez‐Castrillón, José Luis; Vega, Gemma; Abad, Laura; Sanz, Alberto; Mendo, Marcelino; Porrero, Miguel García; Dueñas, Antonio

doi:10.1016/j.jbspin.2006.09.015

Cited by 9 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four cross-sectional studies found higher BMD among BB users;(8–11) but, two of the three longitudinal studies found no difference in BMD among BB users. (12, 13)…”

Section: Introductionmentioning

confidence: 99%

Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study

et al. 2015

View full text Add to dashboard Cite

Purpose Several blood pressure lowering drugs may affect bone mineral density (BMD), leading to altered fracture risk. We examined the effect of blood pressure lowering drugs on BMD using data from the Study of Women’s Health Across the Nation. Methods We conducted a propensity score matched cohort study. Women were initiators of ACE inhibitors (ACEi), beta-blockers (BB), or thiazide diuretics (THZD). Their annualized BMD changes during the 14-years of observation were compared with non-users. Results Among the 2312 eligible women, we found 69 ACEi, 71 BB, and 74 THZD users who were matched by a propensity score with the same number of non-users. THZD users had a slower annual percent decline in BMD compared to nonusers at the femoral neck (FN) (−0.28% vs −0.88%; p = 0.008) and the spine (−0.74% vs −1.0%; p = 0.34), albeit not statistically significant. Annual percent changes in BMD among ACEi and BB users were similar to rates in non-users. In comparison with BB, THZD use was associated with a trend toward less annualized BMD loss at the spine (−0.35% vs −0.60%; p = 0.08) and a similar trend at the FN (−0.39% vs −0.64%; p = 0.08); in comparisons with ACEi, THZD was also associated with less loss at the FN (−0.48% vs −0.82%; p = 0.02), but not at the spine (−0.40% vs −0.56%; p = 0.23). Conclusions Neither ACEi nor BB were associated with improvements in BMD. THZD use was associated with less annualized loss of BMD compared with non-users, as well as compared with ACEi and BB.

show abstract

“…Four cross-sectional studies found higher BMD among BB users;(8–11) but, two of the three longitudinal studies found no difference in BMD among BB users. (12, 13)…”

Section: Introductionmentioning

confidence: 99%

Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In a five-year follow-up study of -blocker users, dose/duration-dependent reduction of fracture risks was observed [53]. Although no change in BMD at the femoral neck was observed in a oneyear follow-up study [58], elevation in BMD was observed in those who had used the drug for two or more years [51]. In view of the above data, it is considered necessary to reexamine duration of use and expression of the effects of each type of drug.…”

Section: (6) Hypertensionmentioning

confidence: 97%

“…Pérez-Castrillón et al conducted a one-year prospective study on 40 male patients with acute myocardial infarction being treated with atorvastin [58]. Of the 40 patients, 30 were taking -blockers.…”

Section: (3) -Blockersmentioning

confidence: 99%

Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective

Fujiwara¹

2010

EMI

View full text Add to dashboard Cite

Osteoporosis, a common disease today, has serious impacts on both patients and society, because prognosis can be complicated and therapy costly. It is therefore important to identify risk factors for osteoporosis to ensure the prevention and early detection. Adjustment of confounding factors is important for accurate evaluation of risk factors. In societies with long average life spans, the number of people with multiple chronic diseases has increased in recent years, resulting in many reports of secondary osteoporosis caused by medication. In this report, we aim to review the possibility that antihypertensive drugs impact osteoporosis by investigating epidemiological research results. As a search strategy, PubMed has been searched using the keywords "osteoporosis," "bone mineral density," "fracture," "hypertension," and "drug-induced" in April 2009. The abstracts have been screened and epidemiological studies have been included. In addition, the authors have also screened reference lists of relevant papers. The results of the present review seem to suggest the possibility that thiazide diuretics and -blockers have positive effects on bone, whereas loop diuretics appear to have adverse effects. In examining effects of drugs on bone, detailed review is necessary on the duration, time since suspension of use, and quantity of drugs used. This review summarizes the impact of antihypertensive drug on bone mineral density and recent patents for the treatment of osteoporosis.

show abstract

“…In a 7-year prospective cohort study (the Study of Osteoporotic Fractures (SOF)), use of BBs had no effect on total hip BMD [30]. In another prospective cohort study of patients after myocardial infarction, there were no significant differences in femoral neck BMD between BB users and BB non-users at 1-year follow-up [31]. In general, there are no RCTs examining the effect of BBs on BMD; the inconsistent findings from the observational studies make it difficult to reach definitive conclusions on the effect BBs have on BMD.…”

Section: Beta-adrenergic Blockers and Bmdmentioning

confidence: 99%

“…Similar to thiazides, there is a body of literature on the effect of BBs on BMD (Table 3; [25][26][27][28][29][30][31]). However, there is a large degree of inconsistency in the findings of these studies, and as such, a definitive conclusion on the effect of BBs on BMD cannot be reached.…”

Section: Beta-adrenergic Blockers and Bmdmentioning

confidence: 99%

Hypertension, Antihypertensive Drugs, and Bone Mineral Density

Hwang

Leu

Butt

2015

Clinic Rev Bone Miner Metab

View full text Add to dashboard Cite

Hypertension and osteoporosis are often present concomitantly in older adults. This narrative review summarizes current knowledge on the effects of hypertension on bone mineral density (BMD) and the effects of major classes of antihypertensive medications on BMD. The relationship between hypertension and BMD has been studied extensively, but remains highly controversial. Commonly prescribed antihypertensive medications, such as thiazides, beta-adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, have mechanisms of action through which they could potentially affect bone metabolism and BMD. The evidence supports a small positive effect of thiazides in terms of increasing BMD or preventing decrease in BMD. Studies of the effect of betaadrenergic blockers and angiotensin-converting enzyme inhibitors on BMD have shown conflicting results. Very few studies have examined the effect of angiotensin II receptor blockers on BMD, and these studies are inconclusive. Studies of calcium channel blockers have found conflicting effects on BMD. Overall, definitive conclusions cannot be reached on the effect of antihypertensive drugs on BMD other than for thiazide diuretics.

show abstract

Effect of β-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction

Cited by 9 publications

References 18 publications

Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study

Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study

Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective

Hypertension, Antihypertensive Drugs, and Bone Mineral Density

Contact Info

Product

Resources

About